Shares of Nevro Corp. (NYSE:NVRO – Get Free Report) have received an average recommendation of “Reduce” from the thirteen research firms that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $19.46.
Several equities analysts have commented on the company. Mizuho lowered their price objective on Nevro from $20.00 to $16.00 and set a “neutral” rating for the company in a research report on Thursday, April 11th. Citigroup lowered Nevro from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $13.50 to $9.00 in a research report on Wednesday, May 22nd. Royal Bank of Canada lowered their price target on Nevro from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Monday, April 15th. Canaccord Genuity Group lowered their price target on Nevro from $17.00 to $11.00 and set a “hold” rating for the company in a research report on Wednesday, May 8th. Finally, Piper Sandler lowered their price target on Nevro from $15.00 to $12.00 and set an “underweight” rating for the company in a research report on Wednesday, May 8th.
View Our Latest Analysis on NVRO
Institutional Investors Weigh In On Nevro
Nevro Trading Down 3.1 %
Shares of NVRO stock opened at $8.34 on Wednesday. The stock has a fifty day moving average of $9.76 and a 200 day moving average of $14.11. Nevro has a 52 week low of $7.85 and a 52 week high of $26.19. The company has a quick ratio of 5.57, a current ratio of 7.38 and a debt-to-equity ratio of 0.77.
Nevro (NYSE:NVRO – Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The medical equipment provider reported ($0.70) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.32. The business had revenue of $101.90 million during the quarter, compared to analyst estimates of $97.90 million. Nevro had a negative return on equity of 27.48% and a negative net margin of 19.17%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.98) earnings per share. As a group, research analysts predict that Nevro will post -2.12 earnings per share for the current fiscal year.
About Nevro
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.
Featured Articles
- Five stocks we like better than Nevro
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- RXO Shares Surge Following New Acquisition Deal
- Stock Sentiment Analysis: How it Works
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Comparing and Trading High PE Ratio Stocks
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.